The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients Using quantitative reverse-transcription polymerase chain
暂无分享,去创建一个
[1] H. Cavé,et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program , 2003, Leukemia.
[2] H. Gschaidmeier,et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment , 2003, Leukemia.
[3] Rocco Piazza,et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. , 2003, The Lancet. Oncology.
[4] Y. Ikeda,et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid , 2002, British journal of haematology.
[5] Sante Tura,et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. , 2002, Blood.
[6] W. Poewe,et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report , 2002, British journal of haematology.
[7] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[8] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[9] R. Krance,et al. Loss of the DEK-CAN fusion transcript in a child with t(6;9) acute myeloid leukemia following chemotherapy and allogeneic bone marrow transplantation , 1997, Leukemia.
[10] T. Lister,et al. Translocation t(6;9)(p23;q34) in acute myeloid leukemia without myelodysplasia or basophilia: two cases and a review of the literature. , 1993, Leukemia.
[11] A. Poustka,et al. The (6;9) chromosome translocation, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34 , 1990, Molecular and cellular biology.
[12] A. Cuneo,et al. Translocation t(6;9) occurring in acute myelofibrosis, myelodysplastic syndrome, and acute nonlymphocytic leukemia suggests multipotent stem cell involvement. , 1989, Cancer genetics and cytogenetics.
[13] H. Gschaidmeier,et al. Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). , 2003, Blood.
[14] Y. Shimamoto,et al. Detection of minimal residual disease in a patient with acute myeloid leukemia and t(6;9) at the time of peripheral blood stem cell transplantation. , 1995, Acta haematologica.
[15] A. Hagemeijer,et al. The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. , 1992, Blood.